Nifedipine Tablet, Extended Release
Product Images NDC 51655-407

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 51655-407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 407 52)

This is a description of a medication with the NDC code 51655-407-52. The medication is NIFEdipine and it comes in extended-release tablets form, USP. The packaging contains a total of 30 tablets that protect from mosts. The rest of the text is not clear enough to determine the actual meaning.*

FDA Label Image

01 (Image 01)

FDA Label Image

02 (Image 02)

The text describes the percentage of patients who experienced adverse effects such as headache, fatigue, dizziness, constipation, and nausea while taking Nifedipine extended-release tablets compared to a placebo. The data was obtained from a sample of 707 patients who took Nifedipine and 266 patients who took a placebo. The percentages indicate that a higher percentage of patients taking Nifedipine experienced constipation and nausea compared to the placebo.*

FDA Label Image

03 (Image 03)

This text presents the incidence of adverse effects reported in a study comparing the use of Nifedipine Capsules versus placebo. The adverse effects are categorized, and the percentage of patients who experienced them in each of the two groups is listed. The study included 226 patients who received Nifedipine Capsules and 235 patients who received placebo. The adverse effects reported included dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough, wheezing, nasal congestion, and sore throat.*

FDA Label Image

04 (Image 04)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.